361 related articles for article (PubMed ID: 20332495)
1. Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer.
Michaud LB
Am J Health Syst Pharm; 2010 Apr; 67(7 Suppl 3):S20-30; quiz S31-3. PubMed ID: 20332495
[TBL] [Abstract][Full Text] [Related]
2. Early breast and prostate cancer and clinical outcomes (fracture).
Chlebowski RT; Tagawa T
Oncology (Williston Park); 2009 Dec; 23(14 Suppl 5):16-20. PubMed ID: 20128324
[TBL] [Abstract][Full Text] [Related]
3. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
Dhanapal V; Reeves DJ
J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
[TBL] [Abstract][Full Text] [Related]
4. Management of bone loss due to endocrine therapy during cancer treatment.
Khan MI
Osteoporos Int; 2023 Apr; 34(4):671-680. PubMed ID: 36656338
[TBL] [Abstract][Full Text] [Related]
5. Background to and management of treatment-related bone loss in prostate cancer.
Berruti A; Tucci M; Terrone C; Gorzegno G; Scarpa RM; Angeli A; Dogliotti L
Drugs Aging; 2002; 19(12):899-910. PubMed ID: 12495366
[TBL] [Abstract][Full Text] [Related]
6. Improving osteoporosis screening, risk assessment, diagnosis, and treatment initiation: role of the health-system pharmacist in closing the gap.
MacLaughlin EJ
Am J Health Syst Pharm; 2010 Apr; 67(7 Suppl 3):S4-8. PubMed ID: 20332497
[TBL] [Abstract][Full Text] [Related]
7. Prevention and treatment of bone loss in patients with nonmetastatic breast or prostate cancer who receive hormonal ablation therapy.
Limburg C; Maxwell C; Mautner B
Clin J Oncol Nurs; 2014 Apr; 18(2):223-30. PubMed ID: 24675258
[TBL] [Abstract][Full Text] [Related]
8. Cancer treatment-induced bone loss.
Adler RA
Curr Opin Endocrinol Diabetes Obes; 2007 Dec; 14(6):442-5. PubMed ID: 17982349
[TBL] [Abstract][Full Text] [Related]
9. Cancer-treatment-induced bone loss, part 2.
Michaud LB; Goodin S
Am J Health Syst Pharm; 2006 Mar; 63(6):534-46. PubMed ID: 16522890
[TBL] [Abstract][Full Text] [Related]
10. Denosumab for cancer-related bone loss.
Dell'Aquila E; Armento G; Iuliani M; Simonetti S; D'Onofrio L; Zeppola T; Madaudo C; Russano M; Citarella F; Ribelli G; Pantano F; Vincenzi B; Tonini G; Santini D
Expert Opin Biol Ther; 2020 Nov; 20(11):1261-1274. PubMed ID: 32835531
[TBL] [Abstract][Full Text] [Related]
11. Bone health management in men undergoing ADT: examining enablers and barriers to care.
Damji AN; Bies K; Alibhai SM; Jones JM
Osteoporos Int; 2015 Mar; 26(3):951-9. PubMed ID: 25526712
[TBL] [Abstract][Full Text] [Related]
12. Aging and osteoporosis in breast and prostate cancer.
VanderWalde A; Hurria A
CA Cancer J Clin; 2011; 61(3):139-56. PubMed ID: 21543824
[TBL] [Abstract][Full Text] [Related]
13. Bone health during endocrine therapy for cancer.
Rachner TD; Coleman R; Hadji P; Hofbauer LC
Lancet Diabetes Endocrinol; 2018 Nov; 6(11):901-910. PubMed ID: 29572126
[TBL] [Abstract][Full Text] [Related]
14. French recommendations on strategies for preventing and treating osteoporosis induced by adjuvant breast cancer therapies.
Bouvard B; Confavreux CB; Briot K; Bonneterre J; Cormier C; Cortet B; Hannoun-Lévi JM; Hennequin C; Javier RM; Kerbrat P; Lespessailles E; Lesur A; Mayeur D; Paccou J; Trémollières F; Vieillard MH; Debiais F
Joint Bone Spine; 2019 Oct; 86(5):542-553. PubMed ID: 31352137
[TBL] [Abstract][Full Text] [Related]
15. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
Israeli RS; Ryan CW; Jung LL
J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
[TBL] [Abstract][Full Text] [Related]
16. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
Ross RW; Small EJ
J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
[TBL] [Abstract][Full Text] [Related]
17. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
19. Prevention and treatment of osteoporosis in women with breast cancer.
Mincey BA; Moraghan TJ; Perez EA
Mayo Clin Proc; 2000 Aug; 75(8):821-9. PubMed ID: 10943237
[TBL] [Abstract][Full Text] [Related]
20. Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer.
Takahashi S
J Bone Miner Metab; 2023 May; 41(3):307-316. PubMed ID: 37036530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
